A 62-year-old Indian man with newly diagnosed Gleason 3+4=7 prostate cancer (PSA 8 ng/mL, T2c, N0, M0) is counselled on treatment options. Which single finding on multiparametric MRI would **most reliably** shift his management from active surveillance to definitive therapy (radical prostatectomy or radiotherapy)?

## MRI Findings and Treatment Escalation in Intermediate-Risk Prostate Cancer ### Clinical Context This patient has **intermediate-risk prostate cancer** (Gleason 7, PSA 8 ng/mL, T2c). Active surveillance is a reasonable option for select intermediate-risk patients, but **evidence of extraprostatic extension (EPE) fundamentally changes the risk profile and mandates definitive therapy**. ### Why EPE is the Critical Discriminator **Key Point:** Extraprostatic extension **upstages the disease from T2 to T3a**, which: 1. Increases biochemical recurrence risk significantly 2. Mandates multimodal therapy (surgery + adjuvant radiotherapy, or radiotherapy + ADT) 3. Contraindicates active surveillance 4. Alters prognosis and long-term cancer control **High-Yield:** On **multiparametric MRI (mpMRI)**, EPE is identified as: - **Breach or bulging of the prostatic capsule** on T2-weighted imaging - **Asymmetric capsular contact** with tumor - **Loss of the rectoprostatic angle** (normally acute; becomes obtuse with EPE) - **Direct visualization of tumor extension into periprostatic fat** This is a **staging finding**, not merely a prognostic marker. ### Comparison of MRI Features | MRI Feature | Diagnostic Value for Staging | Impact on Treatment | |-------------|------------------------------|---------------------| | **Extraprostatic extension** | **Defines T3a stage** | **Mandates definitive therapy** | | Restricted diffusion (low ADC) | Suggests aggressive tumor; present in both T1–T2 and T3 | Prognostic but not staging | | Hypoenhancement on DCE | Suggests higher grade; non-specific | Prognostic but not staging | | Gland asymmetry | Suggests tumor presence; non-specific | Aids localization but not staging | **Clinical Pearl:** A patient with **T2c + Gleason 7 + no EPE** may be offered active surveillance with close monitoring. The **same patient with T3a (EPE)** should proceed to definitive therapy because the risk of progression and metastasis increases substantially. ### Why Other Options Do Not Escalate Treatment - **Focal restricted diffusion (low ADC):** Indicates **aggressiveness** and higher grade but is found in both localized and advanced tumors. Does not define stage and does not mandate escalation from surveillance. - **Hypoenhancement on DCE:** A **prognostic feature** (suggests higher grade) but not a **staging criterion**. Alone, it does not mandate definitive therapy. - **Gland asymmetry:** Suggests tumor presence but is **non-specific** and does not indicate extraprostatic disease. Many localized cancers show asymmetry. **Warning:** Students often confuse **prognostic factors** (Gleason, PSA, ADC, enhancement pattern) with **staging criteria** (T, N, M). Only **staging criteria** (especially EPE) mandate treatment escalation in intermediate-risk disease. [cite:Harrison 21e Ch 97; AUA Prostate Cancer Risk Stratification Guidelines]